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Abstract 
Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation 
encapsulating doxorubicin in a ‘Stealth’ (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology 
confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation 
necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported 
with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a 
diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.
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Introduction 
Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely 
used for the treatment of ovarian cancer. It is a stable 
formulation encapsulating doxorubicin in a ‘Stealth’ (i.e. 
pegylated) liposome with a half-life of about 72 hours. This 
drastically altered pharmacology confers to it a considerably 
lower risk of cardiotoxicity, no acute emesis and near absence 
of alopecia or problems with extravasation necrosis. On the 
other hand, dose-limiting toxicity of PLD is cutaneous [1]. Since 
the original phase I report [2], cutaneous toxicities reported with 
PLD fall into four common categories: the well-known hand-foot 
syndrome (also called palmoplantar erythrodysesthesia, or 
PPE), a diffuse follicular rash, intertrigo-like eruption and 
hyperpigmentation including melanotic macules [3]. 
Pathogenetic mechanisms are in part related to drug or 
metabolite secretion by sweat glands [4]. Consistent with direct 
exposure to the drug or metabolites, its severity is lessened with 
PLD dosing at longer intervals, by regional cooling during drug 
administration and by drugs such as cisplatin that enhance its 
clearance [4]. The current observation confirming enhanced 
toxicity in areas of vitiligo suggests a role for melanin or 




A 52-year-old light-skinned woman of Norwegian-English 
extraction developed Stage IIb fallopian tube cancer in May 
2005, and BRCA1 mutation (her mother died at aged 60 after 
breast and ovarian cancers) was documented. Her surgery 
consisted of hysterectomy, bilateral salpingo-oophorectomy and 
omentectomy. She was initially treated with carboplatin plus 
paclitaxel for six cycles with clinical complete response until 
November 2006. Upon recurrence she received carboplatin plus 
gemcitabine followed by intraperitoneal consolidation with 
cisplatin for five cycles, which was completed in September 
2007. In December 2007, with a rapidly rising CA125 and 
progression of disease in the liver, spleen and pelvic areas, she 
was started on PLD 40 mg/m
2 and given two doses four weeks 
apart before adding oxaliplatin 80 mg/m
2 three weeks after the 
second dose due to a ten-fold rise in CA125. One week later 
she received the third dose of PLD, and this was followed by
discomfort in all pre-existing areas of vitiligo, which became 
deeply erythematous with superficial ulcerations while 
surrounding areas became deeply hyperpigmented (Figure 1a 
and  1b). The patient had no excess exposure to sunlight or 
artificial ultraviolet light during these wintry months. Due to this 
reaction, the fourth dose of Doxil was held, and she was re-
dosed at 30 mg/m
2 every four weeks together with oxaliplatin. 
Except for mild erythema, skin changes resolved. Response to 
the combined treatment, however, only lasted for four months 
and liver metastases became apparent; she was referred to the 
National Cancer Institute for consideration for inclusion in trials 
directed to mutation carriers. However, due to recent exposure 
to a platinum compound, she was started on a tyrosine kinase 
inhibitor but further progression in the liver ensued. 
 
Discussion 
Palmoplantar erythrodysesthesia is the most prominent and 
common dermatologic finding following PLD. In the initial phase 
I studies, cutaneous reactions were more interval- than dose-
dependent and increased in severity more on an every-three-
weeks than on an every-four-weeks schedule [2]. The 
percentage of patients with grade 2–3 skin changes increased, 
being 60% after the third dose. Studies including fluorescent 
detection on the skin surface suggest the drug and/or its 
metabolites are excreted in sweat shortly after PLD infusion is 
started [5]. This prominent excretion route is consistent with 
toxicity often observed in intertriginous areas and also in areas 
where there has been an occlusive dressing or ‘bandaids’ [6] 
(personal observation). The palmar and plantar surfaces may 
be more susceptible to PLD skin toxicity in part because of the 
high density of eccrine sweat glands and/or persistence of a 
drug in a thick stratum corneum. On the other hand, the 
preferential toxicity in vitiligo suggests that diminished 
detoxification by melanocytes or by melanin may play a role. 
Perhaps melanin affords a mechanism to deal with the effects of 
free-radicals generated not only upon exposure to ultraviolet 
light but also to compounds like doxorubicin and its metabolites. 
A recall phenomenon of sunburn in vitiliginous areas of a patient 
treated with PLD who denied any recent sun exposure [7] has in 
fact been reported. The observed toxicity in our patient provides 
additional support for this increased susceptibility and suggests 
that protective mechanisms against cutaneous toxicity from PLD 
may include endogenous melanin production. 
 















Figure 1a: Erythema of pre-existing areas of vitiligo with surrounding hyperpigmented skin changes after doxil infusion. 
 
Figure 1b: Alternative view of erythema of pre-existing areas of vitiligo with surrounding hyperpigmented skin changes after doxil infusion. 
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